Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S.

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the European Congress on Obesity (ECO) in Malaga, Spain, reveal that the drug leads ...

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1, receptor agonist, has shown promise in promoting weight loss and improving ...

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

With age comes wisdom. But you know what else can come with age? Weight gain. Losing weight can also be harder as you grow ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with ...